• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Organigram Launches FAST™ Nanoemulsion Gummies

    11/26/24 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGI alert in real time by email
    • Company Continues to Lead in Innovation with Launch of Edison Sonics Gummies Featuring Groundbreaking FAST™ Nanoemulsion Technology
    • Clinically Proven to Deliver up to ~50% Faster Onset, Improved Bioavailability and Nearly Double the Cannabinoid Delivery at Peak Effect

    Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is thrilled to finally launch Edison Sonics gummies, Organigram's inaugural product powered by FAST™, the Company's groundbreaking nanoemulsion technology and a first-to-market innovation.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241126252025/en/

    (Graphic: Business Wire)

    (Graphic: Business Wire)

    FAST™ products deliver up to ~50% faster onset and improved bioavailability delivering nearly double the cannabinoids at peak effect compared to traditional edible products. This is made possible as FAST™ is an advanced nanoemulsion technology delivery system that breaks down cannabinoids into tiny particles, allowing them to be absorbed more quickly and efficiently during consumption. These results have been scientifically verified through one of the largest pharmacokinetic studies in the cannabis industry, completed in January 2024 in compliance with Health Canada regulations.

    The groundbreaking patent-pending technology, branded FAST ™ (Fast Acting Soluble Technology), is the first innovation to be commercialized by Organigram leveraging the output of the Product Development Collaboration ("PDC"), established to focus on developing next-generation cannabis products.

    "We pride ourselves on consistently being at the forefront of cannabis innovation, pushing boundaries to deliver products that resonate with consumers while firmly being grounded in science and research-based technology," said Borna Zlamalik, Senior Vice President, R&D and Innovation at Organigram. "We are extremely excited about this launch as our Edison Sonics gummies will be a game-changer in the edibles category and FAST™ will redefine how consumers experience cannabis. We are thrilled to be leading the charge in transforming the way cannabis is enjoyed."

    Edison Sonics are launching with two exciting flavours and will be available in all major provinces starting early December:

    • Kiwi Berry Burst (Sativa) – Strawberry, Kiwi, Passionfruit
    • Red Razz Chiller (Indica) – Raspberry, Pomelo

    Each pack will include two gummies, with a total of 10mg THC + 10mg CBD per pack (5mg THC + 5mg CBD per gummy).

    "Organigram continues to raise the bar with consumer-focused innovation, a key characteristic that distinguishes us in a highly competitive industry. Organigram has consistently delivered revolutionary products that go on to become consumer favourites," said Beena Goldenberg, CEO of Organigram. "As we drive our innovation strategy to solidify our leadership in Canada, we're confident that yet again, an innovation-led product by Organigram will be widely embraced by cannabis enthusiasts."

    Inspired by scientific discoveries that shape the world, Edison is here to push the barriers of what's possible. Edison brings the joy and excitement back to cannabis – as the brand willing to wonder and willing to be playfully experimental.

    Edison has a history of delivering industry-leading innovation with products like hash infused pre-rolls and first-to-market Edison JOLTS. Edison Sonics Gummies are a perfect fit within the brand's portfolio, contributing to the ethos of the brand.

    About Organigram Holdings Inc.

    Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary Organigram Inc. is a licensed producer of cannabis, cannabis-derived products and cannabis infused edibles in Canada.

    Organigram is focused on producing high-quality cannabis for adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations (Canada).

    Forward-Looking Information

    This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "estimates", "intends", "anticipates", "believes" or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks disclosed in the Circular, and the Company's most recent annual information form, management's discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241126252025/en/

    Get the next $OGI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What new product did Organigram Holdings Inc. recently launch and what technology powers it?

      Organigram Holdings Inc. launches Edison Sonics gummies with a new FAST™ nanoemulsion technology to enhance cannabinoid delivery.

    • What benefits do Edison Sonics gummies offer compared to traditional cannabis edibles?

      Edison Sonics gummies, powered by FAST™ technology, provide faster onset, improved bioavailability, and increased cannabinoid delivery at peak effect.

    • What flavors are offered in the Edison Sonics gummies and what is the dosage per pack?

      The Edison Sonics gummies are available in two flavors: Kiwi Berry Burst (Sativa) and Red Razz Chiller (Indica), each pack containing 10mg THC + 10mg CBD.

    • How does Organigram plan to maintain its competitive edge in the cannabis industry?

      Organigram aims to establish leadership in the cannabis market through continuous innovation and consumer-focused products like the Edison Sonics gummies.

    • What evidence supports the claims regarding the effectiveness of FAST™ technology used in Edison Sonics gummies?

      The efficacy of FAST™ technology has been supported by a large pharmacokinetic study compliant with Health Canada regulations, completed in January 2024.

    Recent Analyst Ratings for
    $OGI

    DatePrice TargetRatingAnalyst
    1/27/2026Buy
    Canaccord Genuity
    7/17/2024Speculative Buy
    Canaccord Genuity
    4/15/2024Neutral → Buy
    Alliance Global Partners
    1/13/2023Hold → Buy
    Stifel
    1/12/2022Hold → Speculative Buy
    Canaccord Genuity
    1/12/2022$5.70 → $5.30Overweight
    Cantor Fitzgerald
    12/8/2021$5.50 → $5.70Overweight
    Cantor Fitzgerald
    More analyst ratings

    $OGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organigram Reports First Quarter Fiscal 2026 Results

    Strong year-over-year growth supported by Canadian leadership and growing international sales, improving gross margin. Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its results for the first quarter ended December 31, 2025 ("Q1 Fiscal 2026" or "Q1"). Q1 FISCAL 2026 HIGHLIGHTS Gross Revenue: $97.3 million (+46% year-over-year). Net Revenue: $63.5 million (+49% year-over-year). International Revenue: $5.0 million (+51% year-over-year). Adjusted EBITDA2: $5.3 million (+273% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2

    2/10/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram to Report First Quarter Fiscal 2026 Results on February 10, 2026

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its first quarter fiscal 2026 ended December 31, 2025, on Tuesday, February 10, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 10, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://events.q4inc.com/analyst/430252525?pwd=WEt2KbHS To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call.

    2/3/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Extends Innovation Investment with Phylos

    Expanded agreement expected to deliver Organigram enhanced operational security, priority access to selected genetics, and a robust seed pipeline through 2030 Key Highlights: US$3 million investment accelerates Organigram's innovation strategy, providing access to next-generation genetics and strengthening its leadership in seed-based cultivation. Industry-leading seed pipeline, with 30 new, next-generation genetics delivered twice annually through 2030, supporting innovation for recreational and medical markets. Five-year exclusive rights secured for Organigram's chosen cannabis genetics in international markets, with flexibility to add new territories as global expansion contin

    12/31/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Organigram Global

    Canaccord Genuity initiated coverage of Organigram Global with a rating of Buy

    1/27/26 9:29:20 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity resumed coverage on OrganiGram

    Canaccord Genuity resumed coverage of OrganiGram with a rating of Speculative Buy

    7/17/24 12:18:49 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OrganiGram upgraded by Alliance Global Partners

    Alliance Global Partners upgraded OrganiGram from Neutral to Buy

    4/15/24 8:40:01 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    SEC Filings

    View All

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    2/10/26 7:41:44 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    2/3/26 11:10:05 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    1/27/26 7:33:11 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Leadership Updates

    Live Leadership Updates

    View All

    Organigram Announces Appointment of Chief Executive Officer

    Organigram Global Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), the parent company of Organigram Inc., a leading Canadian producer of cannabis, is pleased to announce that James Yamanaka, formerly Global Head of Strategy for British American Tobacco, has been appointed the Company's new Chief Executive Officer (CEO). Mr. Yamanaka is expected to assume the role effective on or about January 15, 2026. Mr. Yamanaka will also join the Company's board of directors when he assumes the role of Chief Executive Officer. Mr. Yamanaka is a seasoned executive, having spent more than 20 years at British American Tobacco, with extensive experience in strategy and general management across

    11/25/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Announces Results of Annual and Special Meeting, including Shareholder Approval of Name Change to Organigram Global Inc.

    Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI) announced today the results of voting at its annual general and special meeting of shareholders (the "Shareholders") held virtually on March 24, 2025 (the "Meeting"). Shareholder Approval of the Name Change and Articles of Amendment At the Meeting, a special resolution approving an amendment to the articles of the Company to change the name of the Company to "Organigram Global Inc." (the "Name Change"), was approved by the affirmative vote of 95.778% of the votes represented at the Meeting. The Name Change remains subject to regulatory approvals, including the approval of the TSX. The TSX has conditionally ap

    3/24/25 8:30:00 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Announces Appointment of Craig Harris to Board of Directors

    Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal at British American Tobacco plc (BAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729497569/en/Craig Harris (Photo: Business Wire) "We are thrilled to welcome Cra

    7/29/24 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Financials

    Live finance-specific insights

    View All

    Organigram Reports First Quarter Fiscal 2026 Results

    Strong year-over-year growth supported by Canadian leadership and growing international sales, improving gross margin. Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its results for the first quarter ended December 31, 2025 ("Q1 Fiscal 2026" or "Q1"). Q1 FISCAL 2026 HIGHLIGHTS Gross Revenue: $97.3 million (+46% year-over-year). Net Revenue: $63.5 million (+49% year-over-year). International Revenue: $5.0 million (+51% year-over-year). Adjusted EBITDA2: $5.3 million (+273% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2

    2/10/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram to Report First Quarter Fiscal 2026 Results on February 10, 2026

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its first quarter fiscal 2026 ended December 31, 2025, on Tuesday, February 10, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 10, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://events.q4inc.com/analyst/430252525?pwd=WEt2KbHS To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call.

    2/3/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Reports Record Fourth Quarter and Fiscal 2025 Results

    Record annual revenue, adjusted EBITDA1, and international sales. Organigram Global Inc (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 recreational cannabis company by market share2, is pleased to announce record results for the fourth quarter and twelve months ended September 30, 2025 ("Q4 Fiscal 2025" or "Fiscal 2025"). All financial information in this press release is expressed in Canadian dollars ("$"). FOURTH QUARTER 2025 FINANCIAL HIGHLIGHTS Gross Revenue: $123.3 million (+76% year-over-year). Net Revenue: $80.1 million (+79% year-over-year). Adjusted Gross Margin1: $30.6 million or 38%. Adjusted EBITDA1: $9.8 million (+69% year-over-year). FISCAL 20

    12/16/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    12/10/24 7:10:15 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    9/3/24 9:30:26 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Organigram Holdings Inc. (Amendment)

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    1/25/24 5:23:26 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care